These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 36286518

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales.
    Karlowsky JA, Hackel MA, Sahm DF.
    Antimicrob Agents Chemother; 2022 Jan 18; 66(1):e0130421. PubMed ID: 34662183
    [Abstract] [Full Text] [Related]

  • 3. Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases.
    Chatwin CL, Hamrick JC, Trout REL, Myers CL, Cusick SM, Weiss WJ, Pulse ME, Xerri L, Burns CJ, Moeck G, Daigle DM, John K, Uehara T, Pevear DC.
    Antimicrob Agents Chemother; 2021 Jul 16; 65(8):e0055221. PubMed ID: 34001510
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination.
    Fratoni AJ, Avery LM, Nicolau DP, Asempa TE.
    J Antimicrob Chemother; 2022 Dec 23; 78(1):93-100. PubMed ID: 36272135
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).
    Sader HS, Carvalhaes CG, Huband MD, Mendes RE, Castanheira M.
    Eur J Clin Microbiol Infect Dis; 2023 Apr 23; 42(4):453-459. PubMed ID: 36810724
    [Abstract] [Full Text] [Related]

  • 9. Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing.
    Sader HS, Lindley J, Deshpande LM, Doyle T, Castanheira M.
    Diagn Microbiol Infect Dis; 2022 Jun 23; 103(2):115673. PubMed ID: 35390644
    [Abstract] [Full Text] [Related]

  • 10. In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales.
    Lomovskaya O, Castanheira M, Lindley J, Rubio-Aparicio D, Nelson K, Tsivkovski R, Sun D, Totrov M, Loutit J, Dudley M.
    Antimicrob Agents Chemother; 2023 Nov 15; 67(11):e0044023. PubMed ID: 37800963
    [Abstract] [Full Text] [Related]

  • 11. In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial.
    Stewart AG, Cottrell K, Henderson A, Vemuri K, Bauer MJ, Paterson DL, Harris PNA.
    Microbiol Spectr; 2021 Sep 03; 9(1):e0022621. PubMed ID: 34232101
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS, Castanheira M, Flamm RK.
    Antimicrob Agents Chemother; 2017 Apr 03; 61(4):. PubMed ID: 28069649
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014-2019.
    Wise MG, Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF.
    Microb Drug Resist; 2023 Aug 03; 29(8):360-370. PubMed ID: 37253158
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals.
    Kimbrough JH, Maher JM, Sader HS, Castanheira M, Mendes RE.
    Microbiol Spectr; 2024 Oct 10; ():e0147424. PubMed ID: 39387599
    [Abstract] [Full Text] [Related]

  • 16. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
    Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN.
    Antimicrob Agents Chemother; 2012 Sep 10; 56(9):4779-85. PubMed ID: 22733066
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC, Stone GG.
    Ann Clin Microbiol Antimicrob; 2020 Apr 01; 19(1):14. PubMed ID: 32238155
    [Abstract] [Full Text] [Related]

  • 19. In Vitro and In Vivo Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae.
    Gupta A, Malik S, Kaminski M, Landman D, Quale JM.
    Microb Drug Resist; 2022 Apr 01; 28(4):419-424. PubMed ID: 35451880
    [Abstract] [Full Text] [Related]

  • 20. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
    Stewart AG, Bauer MJ, Butkiewicz D, Hinton A, Henderson A, Harris PNA, Paterson DL.
    Int J Antimicrob Agents; 2023 Aug 01; 62(2):106858. PubMed ID: 37211261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.